Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

June 30, 2007

Conditions
Dyslipidemia
Interventions
DRUG

CP-778,875

Trial Locations (31)

10550

Pfizer Investigational Site, Mount Vernon

21201

Pfizer Investigational Site, Baltimore

23225

Pfizer Investigational Site, Richmond

23249

Pfizer Investigational Site, Richmond

23294

Pfizer Investigational Site, Richmond

23606

Pfizer Investigational Site, Newport News

30094

Pfizer Investigational Site, Conyers

30342

Pfizer Investigational Site, Atlanta

32435

Pfizer Investigational Site, DeFuniak Springs

32541

Pfizer Investigational Site, Destin

32901

Pfizer Investigational Site, Melbourne

33458

Pfizer Investigational Site, Jupiter

35801

Pfizer Investigational Site, Huntsville

36207

Pfizer Investigational Site, Anniston

37660

Pfizer Investigational Site, Kingsport

40504

Pfizer Investigational Site, Lexington

52242

Pfizer Investigational Site, Iowa City

53209

Pfizer Investigational Site, Milwaukee

60612

Pfizer Investigational Site, Chicago

65807

Pfizer Investigational Site, Springfield

68131

Pfizer Investigational Site, Omaha

73103

Pfizer Investigational Site, Oklahoma City

74136

Pfizer Investigational Site, Tulsa

77030

Pfizer Investigational Site, Houston

77802

Pfizer Investigational Site, Bryan

78229

Pfizer Investigational Site, San Antonio

89106

Pfizer Investigational Site, Las Vegas

90057

Pfizer Investigational Site, Los Angeles

94598

Pfizer Investigational Site, Walnut Creek

94904

Pfizer Investigational Site, Greenbrae

98902

Pfizer Investigational Site, Yakima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY